EN | RU
EN | RU

Help Support

Back

Clinical and cost impact of tapering or withdrawal of TNF- α inhibitors in RA patients

Clinical and cost impact of tapering or withdrawal of TNF- α inhibitors in RA patients Clinical and cost impact of tapering or withdrawal of TNF- α inhibitors in RA patients
Clinical and cost impact of tapering or withdrawal of TNF- α inhibitors in RA patients Clinical and cost impact of tapering or withdrawal of TNF- α inhibitors in RA patients

What's new?

Decision making regarding treatment withdrawal or dose tapering should be made carefully as withdrawal of anti-TNF treatment significantly reduced the 5-year health care cost but also caused poor clinical outcomes in RA patients.

Today, rheumatoid arthritis (RA) estimated 0.24% prevalence with considerable economic costs worldwide. Strategies like anti-TNF (tumour necrosis factor-α) maintenance, dose tapering or withdrawal exhibits unique role in managing RA with improved symptoms, cost-effectiveness as well as obstructing radiographic progression. 

To evaluate health care costs and disease control, Aletaha D and colleagues conducted a 5-year real-world treatment which involves comparison of tumour necrosis factor-α inhibitors (anti-TNFs) adalimumab, etanercept or infliximab maintenance with dose tapering or withdrawal treatments. This estimation was done by using a -year Markov model with a 1-month cycle. The model determined the medical and anti-TNF costs and time (time to loss of disease control and to regaining control after the treatment). For analysis patients with RA who achieved remission ([DAS28] < 2.6) or had low disease activity (LDA; DAS28 < 3.2) were taken. Fourteen studies which included 2309 patients were meta-analyzed to estimate the risk of losing disease control which is adjusted for RA patient type, treatment strategy, anti-TNF and model entry criterion (remission or LDA).

According to analysis, the anti-TNF maintenance obtained comparable 5-year total costs (€67,100-€72,100), which was higher than anti-TNF withdrawal and tapering (€37,900-€59,700 vs €47,500-€59,200). The total costs were higher among established RA patients (€45,900-€72,100) as compared to early RA patients (€37,900-€71,700). The longest time to loss of disease control was noted in maintenance strategy (range, 27.3-47.1 months) whereas shortest in withdrawal strategy (range, 6.9-30.5 months). 

Source:

Clinico Economics and Outcomes Research

Article:

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-a inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

Authors:

Aletaha D et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: